Editas Medicine Q2 net loss narrows to $18.2 million; director Ellinor appointed
Editas Medicine reported a second-quarter 2026 net loss of $18.2 million, or $0.15 per share, down from $53.2 million, or $0.63 per share, a year earlier, while collaboration revenue rose to $11.9 million from $3.6 million. The company said its cash runway now extends into the second half of 2028 following a May public offering, and it added Patrick Ellinor, M.D., Ph.D. to its board effective August 6, 2026.
Key points
- Net loss of $18.2 million, or $0.15 per share, for the quarter ended June 30, 2026, versus $53.2 million, or $0.63 per share, a year earlier.
- Collaboration and other R&D revenues of $11.9 million, up from $3.6 million, mainly from recognition of deferred revenue tied to the BMS collaboration.
- Cash and cash equivalents of $211.6 million at June 30, 2026, following a May public offering with $125.0 million in gross proceeds.
- Elliott Levy, M.D., resigned from the board effective August 4, 2026; Patrick Ellinor, M.D., Ph.D. was appointed an independent director effective August 6, 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.